Tests a blood test for early cancer detection in people with symptoms
Tests a blood test to help detect cancer in adults with symptoms.
Plain-language title generated from the registry record
Registry title: Clinical Validation of an MCED Test in Symptomatic Populations (K-ACCELERATE)
Key facts
- Where
- Ho Chi Minh City, VietnamSee the site
Where in Vietnam
- Medical Genetics InstituteHo Chi Minh City, VietnamNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Gene Solutions
- Trial code
- NCT06391749
- Record updated
- 16 July 2025
- Original description
To evaluate the diagnostic performance of blood-based SPOT-MAS test in symptomatic individuals, the investigators sought to launch a prospective multicenter study, named K-ACCELERATE. The study aims to recruit 1,000 participants who develop symptoms and signs specific to the top five common cancer types including breast, colorectal, gastric, liver and lung cancer.Read full original descriptionShow less
K-ACCELERATE: A Multi-center Prospective Trial to Evaluate Clinical Utility of Multi Cancer Early Detection Test as a Triage Test for Symptomatic Participants
To evaluate the diagnostic performance of blood-based SPOT-MAS test in symptomatic individuals, the investigators sought to launch a prospective multicenter study, named K-ACCELERATE. The study aims to recruit 1,000 participants who develop symptoms and signs specific to the top five common cancer types including breast, colorectal, gastric, liver and lung cancer.
Primary objective: Evaluate the performance of the SPOT-MAS test in detecting cancer in symptomatic populations.
Secondary objectives: Evaluate the feasibility of incorporating SPOT-MAS as a triage test into primary care to increase the detection rates of malignant cancer while minimizing unnecessary referrals to invasive procedures.
Inclusion: Male or Female, aged 18 years or above Participants are willing and able to give informed consent for participation in the study; Participants aged over 18 years; Individuals presenting symptoms associated witht breast, colorectal, gastric, liver and lung cancer (see below) and being referred for low resolution imaging tests including US breast, chest x-ray, colorectal endoscopy, gastroscopy, US abdomen or relevant diagnostic modalities; Symptoms and Signs; Breast symptoms: Axillary lump/mass; Breast lump/mass; Breast pain; Nipple discharges; Breast skin change; Lung symptoms: Symptoms for more than 3 weeks: Dyspnea (shortness of breath); Chest pain; Cough that does not go away; Hemoptysis (coughing up blood); Colorectal symptoms: Hematochezia (blood in the stool); Diarrhea ≥ 3 weeks; Constipation ≥ 3 weeks; Abdominal pain ≥ 3 weeks; Gastric symptoms: Epigastric pain ≥ 3 weeks; Hematemesis (vomiting blood); Liver symptoms: Jaundice (yellowing of the skin and eyes); Right upper quadrant (RUQ) pain; Significant weight loss (≥10% of body weight in previous 6 months); Consent to undertake high resolution imaging tests or biopsy upon receiving positive test results from either SPOT-MAS or low-resolution imaging tests.
Exclusion: Having a history of invasive cancer diagnosed within the last 5 years; Having undergone treatment for invasive cancer within the last 5 years; Having a history of bone marrow transplant or whole blood transfusion within the last 3 months; Being pregnant.